Simplify Logo

Full-Time

Senior Scientist I

Translational Medicine

Posted on 6/27/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Specializes in precision oncology therapies

Hardware
Biotechnology
Healthcare

Senior

San Carlos, CA, USA

Category
Bioinformatics
Genomics
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Ph.D. in cancer biology, cell/molecular biology or equivalent with 3+ years of post-doctoral and/or industry experience, or an M.S. with 6+ years of industry experience
  • Experience in Translational Medicine with clinical-stage oncology drug development
  • Demonstrated knowledge of clinically relevant biomarker approaches across a range of technology platforms (NGS, RNAseq, IHC, mIF, qPCR/ddPCR, etc.)
  • NGS and genomic biomarker data analysis experience
  • Experience working with central laboratories and CROs supporting biomarker analysis
  • Strong interpersonal and communication skills
  • Commitment to Revolution Medicines’ Core Values
Responsibilities
  • Define and execute translational and biomarker strategies for Revolution Medicine’s clinical-stage oncology programs
  • Ensure that clinical biomarker plans are developed and implemented efficiently and aligned with the strategic needs of the program
  • Manage external biomarker analysis at contract research organizations (CROs)
  • Collaborate with Translational Medicine team members in biomarker operations and clinical bioinformatics
  • Evaluate new technologies to enable exploratory biomarkers
  • Represent Translational Medicine within project/program teams
  • Contribute to the development of clinical protocols, laboratory manuals, regulatory submissions, abstracts, and publications
  • Collaborate across internal functions including translational sciences, clinical development, clinical operations, biostatistics, data management, and clinical pharmacology

### Welcome to Revolution Medicines, crafting the future of oncology with precision. Our focus is on advancing RAS(ON) inhibitors and RAS Companion inhibitors, marked by the remarkable journey of our lead product, RMC-4630, through its clinical phases. Supported by a team of passionate oncology experts, we are steadfast in our mission to develop treatments that precisely target oncogenic mutations, promising a brighter, healthier tomorrow for patients everywhere. ###

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

17%

1 year growth

46%

2 year growth

111%
INACTIVE